To compare adjunctive stenting for the patients with symptomatic atherosclerotic intracranial stenosis with optimal medical therapy alone.
- Clopidogrel (Plavix®)Drug
Other Names: Plavix, Clodelib, Clovelen Intervention Desc: Antiplatelet agent
- Aspirin Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2; antipyretic
- Probucol Drug
Other Names: Probucol is produced by Otsuka Pharmaceutical Intervention Desc: Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease.
Prospective, randomized, multi-center clinical trial.
Baseline angiography or MR angiography, CT and CT-perfusion and repeat at 6 months. NIHSS at 12 months. Participants will be randomized into the medical treatment group, or combined treatment group (medical therapy plus stent-assisted angioplasty) in the ratio of 1:2. All recruited patients will receive dual anti-platelets (aspirin and clopidogrel) and probucol. Modifiable risk factors will be controlled by life-style adjustment and/or pharmacological therapy according to major international guidelines. Participants in combined treatment group will additionally undergo stent- assisted angioplasty for the offending intracranial stenosis with Apollo stent. All patients will be scheduled clinical visits by the end of 1st, 3rd, 6th, 9th and 12th months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Ipsilateral stroke, fatal or non-fatal, within 12 months; events of clinically-driven emergency revascularization related to the treated stenosis; mRS at 12 month.|
|Secondary||Stroke and death unrelated to the target stenosis; acute myocardial infarction within 12 months; follow up cerebral angiography or MR angiography, CT and CT-perfusion at 6 month; NIHSS at 12 month.|